Compare RBKB & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | HUMA |
|---|---|---|
| Founded | 1860 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 191.4M |
| IPO Year | 2018 | N/A |
| Metric | RBKB | HUMA |
|---|---|---|
| Price | $17.07 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 45.2K | ★ 18.0M |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,984,000.00 | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | $85.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.41 | $0.55 |
| 52 Week High | $17.99 | $2.84 |
| Indicator | RBKB | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 36.22 |
| Support Level | $15.10 | $0.65 |
| Resistance Level | $17.92 | $1.26 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 45.45 | 10.91 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.